41![Microsoft Word - 140714_FDA agreement for Phase 3 Recurrent BV trial Microsoft Word - 140714_FDA agreement for Phase 3 Recurrent BV trial](https://www.pdfsearch.io/img/442186c5640ff8ef6b671befc3fe4a8c.jpg) | Add to Reading ListSource URL: www.starpharma.comLanguage: English - Date: 2014-07-13 20:48:03
|
---|
42![4 Nanodevice Technologies – From New Functions of Extreme Substances to Telecommunication Technologies – 4-1 Controlling Intermolecular Interactions using Nano-Structural Molecules OTOMO Akira, YOKOYAMA Shiyoshi, FUR 4 Nanodevice Technologies – From New Functions of Extreme Substances to Telecommunication Technologies – 4-1 Controlling Intermolecular Interactions using Nano-Structural Molecules OTOMO Akira, YOKOYAMA Shiyoshi, FUR](https://www.pdfsearch.io/img/947fac62c982fd08fd8908e7307978f4.jpg) | Add to Reading ListSource URL: www.nict.go.jpLanguage: English - Date: 2013-11-21 18:52:27
|
---|
43![Starpharma’s docetaxel superior to Taxotere® across multiple cancer types Melbourne, Australia; Thursday 6 December 2012: Starpharma (ASX:SPL; OTCQX:SPHRY) today announced the results of animal trials which show its d Starpharma’s docetaxel superior to Taxotere® across multiple cancer types Melbourne, Australia; Thursday 6 December 2012: Starpharma (ASX:SPL; OTCQX:SPHRY) today announced the results of animal trials which show its d](https://www.pdfsearch.io/img/200f9cac024bc324926977b131692f2f.jpg) | Add to Reading ListSource URL: www.starpharma.comLanguage: English - Date: 2012-12-05 20:32:48
|
---|
44![Starpharma’s docetaxel demonstrates targeted tumour delivery Melbourne, Australia; 29th October 2012: Starpharma Holdings Ltd (ASX:SPL;OTCQX: SPHRY) today reported significant tumour-targeting results with its propriet Starpharma’s docetaxel demonstrates targeted tumour delivery Melbourne, Australia; 29th October 2012: Starpharma Holdings Ltd (ASX:SPL;OTCQX: SPHRY) today reported significant tumour-targeting results with its propriet](https://www.pdfsearch.io/img/837cdedc9f72f86f4b8a3d508a82ad5f.jpg) | Add to Reading ListSource URL: www.starpharma.comLanguage: English - Date: 2012-10-28 19:02:03
|
---|
45![4-3 Development of Molecular-beam Apparatus with Spray-jet Technique YAMADA Toshiki, SUZUKI Hitoshi, SHINOHARA Hidenori, and MASHIKO Shinro We developed a molecular-beam apparatus with a spray-jet technique that produces 4-3 Development of Molecular-beam Apparatus with Spray-jet Technique YAMADA Toshiki, SUZUKI Hitoshi, SHINOHARA Hidenori, and MASHIKO Shinro We developed a molecular-beam apparatus with a spray-jet technique that produces](https://www.pdfsearch.io/img/d2147522bdde54587d76b5ae3bb86c1d.jpg) | Add to Reading ListSource URL: www.nict.go.jpLanguage: English - Date: 2013-11-21 18:52:59
|
---|
46![Half Year Results Period ended 31 December 2007 Melbourne, Australia; 21 February 2008: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced its financial results for the six months ending 31 December 2007. Half Year Results Period ended 31 December 2007 Melbourne, Australia; 21 February 2008: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced its financial results for the six months ending 31 December 2007.](https://www.pdfsearch.io/img/b3db3799027faa1b40e9a9ff00f30f30.jpg) | Add to Reading ListSource URL: www.starpharma.comLanguage: English - Date: 2011-06-26 22:21:36
|
---|
47![Starpharma’s Dendrimer-Docetaxel eliminates neutropenia Melbourne Australia; 24 October[removed]Starpharma Holdings Ltd (ASX: SPL; OTCQX: SPHRY) today announced additional positive results for its dendrimer formulation Starpharma’s Dendrimer-Docetaxel eliminates neutropenia Melbourne Australia; 24 October[removed]Starpharma Holdings Ltd (ASX: SPL; OTCQX: SPHRY) today announced additional positive results for its dendrimer formulation](https://www.pdfsearch.io/img/bb802c0e3e7b567e754e888aaee2b423.jpg) | Add to Reading ListSource URL: www.starpharma.comLanguage: English - Date: 2013-10-23 21:11:12
|
---|
48![Starpharma Interim Report and Half-year Financial Results Melbourne, Australia; 24 February 2014: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today released its interim report and financial results for the half-ye Starpharma Interim Report and Half-year Financial Results Melbourne, Australia; 24 February 2014: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today released its interim report and financial results for the half-ye](https://www.pdfsearch.io/img/c876a352aa33469efaebc3c605684cf5.jpg) | Add to Reading ListSource URL: www.starpharma.comLanguage: English - Date: 2014-02-23 21:53:43
|
---|
49![IN THIS ISSUE › Phase 3 clinical trial results for treatment of bacterial vaginosis › Rapid resolution of symptoms; strong patient acceptability for VivaGel® IN THIS ISSUE › Phase 3 clinical trial results for treatment of bacterial vaginosis › Rapid resolution of symptoms; strong patient acceptability for VivaGel®](https://www.pdfsearch.io/img/761e2dfdbe0b6b46cce0a53aadbb10bb.jpg) | Add to Reading ListSource URL: www.starpharma.comLanguage: English - Date: 2012-12-18 18:48:48
|
---|
50![Starpharma Annual Report[removed]Starpharma Holdings Limited Baker Building 75 Commercial Road, Melbourne VIC 3004 Australia Starpharma Annual Report[removed]Starpharma Holdings Limited Baker Building 75 Commercial Road, Melbourne VIC 3004 Australia](https://www.pdfsearch.io/img/872c1bfdb4f10b98ca08a6bd84723e98.jpg) | Add to Reading ListSource URL: www.starpharma.comLanguage: English - Date: 2011-06-26 22:21:33
|
---|